Current management of hepatocellular carcinoma: An Eastern perspective

Yim, Hyung Joon

doi:10.3748/wjg.v21.i13.3826

Cited by 50 publications

(52 citation statements)

References 177 publications

(224 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nowadays, BCLC staging system is frequently applied in Western guidelines. Although BCLC is accepted in western countries, many Asian-pacific experts do not fully agree with its principle because has very strict guidelines for treatments and only early and very early stage of HCC are fitted for curative treatments (BCLC stage 0 and A) (10,49,50). However, in our study patients that received curative treatment were situated mainly in BCLC A and B classes.…”

Section: Discussioncontrasting

confidence: 43%

Curative Intent Treatment of Hepatocellular Carcinoma - 844 Cases Treated in a General Surgery and Liver Transplantation Center

Grigorie¹,

Alexandrescu²,

Smira³

et al. 2017

chr

View full text Add to dashboard Cite

RezumatObiectivul acestui studiu este acela de a evalua rezultatele pacienţilor trataţi pentru hepatocarcinom (CHC) într-un centru de Chirurgie Generalã şi Transplant Hepatic. Material şi metode: Acest studiu retrospectiv include 844 pacienţi diagnosticaţi cu CHC şi trataţi chirurgical cu intenţie de radicalitate. Singurele metode de tratament curativ pentru CHC, la ora actualã sunt reprezentate de rezecţia hepaticã (RH) şi transplantul hepatic (TH). Ablaţia tumoralã poate fi indicatã în tratamentul CHC precoce, în cazurile la care rezecţia sau transplantul hepatic nu se pot efectua. La 518 pacienţi s-a practicat rezecţie hepaticã, 162 au beneficiat de transplant hepatic, iar 164 pacienţi au fost trataţi prin distrucţie cu radiofrecvenţã (RFA). 615 pacienţi (73%) au prezentat cirozã hepaticã. Rezultate: Morbiditatea şi mortalitatea înregistrate pentru întreg lotul de pacienţi au fost de 30% şi respectiv 4,3%. Supravieţuirea la 5 ani a fost de 39% cu diferenţe semnificative statistic între pacienţii la care s-a practicat RH comparativ cu cei transplantaţi şi Chirurgia (2017)

show abstract

Section: Discussioncontrasting

confidence: 43%

Curative Intent Treatment of Hepatocellular Carcinoma - 844 Cases Treated in a General Surgery and Liver Transplantation Center

Grigorie¹,

Alexandrescu²,

Smira³

et al. 2017

chr

View full text Add to dashboard Cite

show abstract

“…Although several chemotherapeutic agents are currently available for treating HCC, these drugs are frequently result in severe side effects, such as bone marrow suppression, liver and kidney function disorder and a lowered immunological function (Yim et al, 2015;Stotz et al, 2015;Newell et al, 2008). Therefore, developing new therapeutic anti-tumor drugs with better effectiveness and lower toxicity have gained more and more attention.…”

Section: Discussionmentioning

confidence: 99%

Platycodin D exerts anti-tumor efficacy in H22 tumor-bearing mice via improving immune function and inducing apoptosis

Tian

Liu

et al. 2016

J. Toxicol. Sci.

View full text Add to dashboard Cite

-Platycodin D (PD), a major saponin derived and isolated from the roots of Platycodon grandiflorum, exerts potent growth inhibition and strong cytotoxicity against various cancer cell lines. However, the anti-tumor efficacy of PD on H22 hepatocellular carcinoma remains unknown. In the present study, we aimed to explore the anti-hepatoma activity in vivo and the underlying mechanism of PD in H22 tumor-bearing mice. The results revealed that PD could considerably suppress tumor growth with no significant side effects on immune organs and body weight. Further investigations showed that the levels of serum cytokines, including interferon gamma (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-2 (IL-2), were enhanced by PD administration. On the other hand, PD inhibited the production of vascular endothelial growth factor (VEGF) in serum of H22 tumor mice. Additionally, the observations from H&E and Hoechst 33258 staining results demonstrated that PD noticeably induced apoptosis in H22 hepatocellular carcinoma cells. Importantly, immunohistochemical analysis showed that PD treatment increased Bax expression and decreased Bcl-2 and VEGF expression of H22 tumor tissues in a dose-dependent manner. Taken together, the findings in the present investigation clearly demonstrated that the PD markedly suppressed the tumor growth of H22 transplanted tumor in vivo at least partly via improving the immune functions, inducing apoptosis, and inhibiting angiogenesis.

show abstract

“…However, to date, the incidence and mortality rate of liver cancer remain at a high level. Even though locoregional therapies such as hepatic artery ligation Tables I and II (samples were collected or embolization have been developed in the past decades, they have failed to significantly prolong the overall survival of liver cancer patients (22)(23)(24). Despite decades of efforts made by researchers worldwide, the investigation of anti-liver cancer drugs is stagnant (25)(26)(27)(28).…”

Section: Discussionmentioning

confidence: 99%

A novel cell cycle blocker extracted from Stellera chamaejasme L. inhibits the proliferation of hepatocarcinoma cells

Kan

Chen

et al. 2016

Oncology Reports

View full text Add to dashboard Cite

Abstract. Currently, liver cancer is the sixth most prevalent cancer and the third most common cause of cancer-related death. However, effective chemotherapeutic drugs with low drug resistance and few side-effects for the clinical treatment of liver cancer are lacking. Therefore, the search for novel drugs to compensate for the defects of existing drugs is urgently needed. Herein, we successfully screened an extract named from Stellera chamaejasme L. (SCL), a historically confimed antitumor plant, through a novel extraction platform. In the present study, we firstly screened the anticancer effect of ESC by the sulforhodamine B (SRB) cell proliferation assay in a wide range of malignant cell lines, including A549, NCI-H157, NCI-H460, SK-HEP-1 and HepG2. With the highest inhibitory rate in hepatocarcinoma cells, we further identified the tumor-suppressive efficacy and the safety of ESC in an H22 hepatocarcinoma xenograft model in vivo. In a mechanistic study, flow cytometry and western blot analysis were performed to evaluate the effects of ESC on the induction of cell apoptosis, intervention of cell cycle distribution and its influence on key G2/M-phase regulators. The results showed that ESC significantly inhibited the cell growth of liver cancer cell lines. Accordingly, the tumor inhibition rate was also increased following ESC administration with little systemic toxicity in H22-transplanted mice. Mechanistically, ESC caused obvious G2/M-phase arrest in both the SK-HEP-1 and HepG2 cell lines without cell apoptosis. Furthermore, cyclin B1 was downregulated, while the phosphorylation level of CDK1 was increased in response to ESC treatment. All these data confirmed that ESC possesses potent anti-proliferative efficacy for hepatocarcinoma through the induction of cyclinmediated cell cycle arrest. Thus, ESC is a promising candidate for hepatocarcinoma treatment in the future. IntroductionAs one of the major global public health issues, cancer greatly threatens human survival and has become the leading cause of mortality of humankind in this century (1). Clinically, during the rapid development of anticancer strategies, chemotherapy has consistently played an important role in cancer treatment. To date, classical botanical agents, as represented by paclitaxel or vincristine, are still first-line drugs and are widely applied as the primary choice against multiple malignancies (2). Benefitting from these agents, treatment effectiveness and the survival rate of cancer patients have greatly improved in recent years. However, in spite of the satisfactory tumor-suppressive activities, with their extensive application worldwide, growing evidence reveals that side-effects and drug resistance are still the leading obstacles largely limiting the clinical use of classic tumor-toxic agents (3).In recent years, liver cancer has become one of the most prevalent types of cancer and is the third most common cause of cancer-related mortality (4,5). Notably, its incidence and mortality rank second among Chinese cancer patients (6) an...

show abstract

Current management of hepatocellular carcinoma: An Eastern perspective

Abstract: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death, especially in Eastern areas. With

Cited by 50 publications

References 177 publications

Curative Intent Treatment of Hepatocellular Carcinoma - 844 Cases Treated in a General Surgery and Liver Transplantation Center

Curative Intent Treatment of Hepatocellular Carcinoma - 844 Cases Treated in a General Surgery and Liver Transplantation Center

Platycodin D exerts anti-tumor efficacy in H22 tumor-bearing mice via improving immune function and inducing apoptosis

A novel cell cycle blocker extracted from Stellera chamaejasme L. inhibits the proliferation of hepatocarcinoma cells

Contact Info

Product

Resources

About